Project Grant R01AI184474

Award Date 6/11/25
Completion Date 5/31/30
Dollars Obligated $829K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award, valued at $304,280.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will fund research focused on integrating bacterial genomics, proteomics, and patient health data to clarify risk factors for Enterococcal infective endocarditis (IE) infections. The key products and services to be delivered include: Curation and assessment of patient health and...
This $462,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the human microbiome regulates neutrophil immune responses and impacts sepsis outcomes. The key objectives are to: Elucidate the mechanism by which the microbiome "primes" or trains human neutrophils during homeostasis, leading to differential inflammatory responses....
This $168,145 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports a retrospective and prospective study to better define the clinical significance of enteropathogenic (EPEC) and enteroaggregative (EAEC) E. coli in adult patients in Seattle, WA. The key products and services to be delivered include: 1) a retrospective analysis of the clinical features,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the mechanisms by which the gut microbiota, specifically short-chain fatty acids, inhibit the growth of the enteric pathogen Yersinia enterocolitica. The $195,213 award, spanning from November 2024 to October 2026, will fund in vitro studies and mouse model experiments to elucidate how...
This federal Project Grant award for $637,275 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to uncover the mechanisms behind how gram-negative bacterial pathogens rapidly develop tolerance to chemical stressors like antibiotics. The research aims to determine how bacteria can inhibit the functioning of existing porin proteins in their outer membrane within minutes of exposure to...
This $479,730 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to elucidate the mechanisms by which prophages (viruses integrated into bacterial genomes) modulate the production of the antimicrobial compound reuterin in the probiotic gut bacterium Limosilactobacillus reuteri. The research aims to: 1) characterize the interplay between a prophage-derived protein...
This $171,089 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into the genetic and phenotypic adaptations of vancomycin-resistant Enterococcus faecium (VREFM) during recurrent bloodstream infections. The key objectives are to: 1) conduct comparative genomic analyses of VREFM isolates from patients with recurrent infections to identify genetic signatures associated...
This federal Project Grant award totaling $810,312.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to investigate environmental reservoirs and transmission dynamics of multi-drug resistant Enterobacterales (MDR ENT) in the Chicago area. The key objectives are to: 1) Profile MDR ENT and mobile antibiotic resistance genes in Greater Chicago waterways to identify environmental...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $749,417 to support research focused on the development of novel bactericidal antibiotics targeting the lipoprotein transport pathway in Gram-negative bacteria. The research aims to diversify and improve an existing modular antibiotic platform to synthesize new candidate antibiotics with enhanced potency and...
This $948,482 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research into the molecular mechanisms of the YbtPQ bacterial importer, a novel type of ATP-binding cassette (ABC) transporter found in uropathogenic E. coli. The primary goals are to define the substrate selectivity and inhibitory mechanisms of YbtPQ, as well as understand its unique structural motifs. Researchers at the University of...

This $828,820 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the molecular mechanisms by which the commensal bacterium Enterococcus faecalis transitions from a gut resident to a pathogen that can breach the intestinal barrier and cause systemic infections.

The key objectives are to: 1) define how E. faecalis disrupts endoplasmic reticulum (ER) proteostasis in epithelial cells, 2) establish that E. faecalis-induced ER stress responses compromise intestinal barrier function, and 3) test if disabling ER stress sensors in vivo can thwart enterococcal translocation during antibiotic-induced dysbiosis. The research will leverage the multidisciplinary expertise of the award recipients at Weill Medical College of Cornell University in E. faecalis pathogenesis, ER stress biology, and intestinal physiology. The findings could lead to new treatments to prevent or control systemic infections caused by gut-resident enterococci.

Generated 7/1/25, 2:09 AM